Effect of Microporous Polysaccharide Hemospheres (MPH) on Bleeding after Endoscopic Sinus Surgery

Antisdel, Jastin L.; West-Denning, Jackie L.; Sindwani, Raj

doi:10.1016/j.otohns.2009.06.078

Cited by 68 publications

(72 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This solution is used as a cell culture scaffold in basic research on regenerative medicine, and no reports to date have identified serious adverse effects in cultured cells or laboratory animals such as toxicity or carcinogenicity. 6,7) Unlike hemostatic agents such as oxidized cellulose or starch-based absorbent topical preparations that stem blood flow by the formation of clots, 8,9) the hemostatic action of TDM-621 is realized by modification of physical properties upon a change in pH to seal off the bleeding point in the same manner as an approved collagen-based absorbent topical hemostatic agent and physiological tissue adhesive (fibrin glue).…”

Section: Discussionmentioning

confidence: 99%

Novel Infectious Agent-Free Hemostatic Material (TDM-621) in Cardiovascular Surgery

Masuhara

Fujii

Watanabe

et al. 2012

Ann Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Subjects: Currently, hemostatic materials made from human blood components and animalderived collagen is used for controlling operative hemorrhage in the cardiovascular surgery field. In this study, we focused on an entirely synthetic self-assembling peptide (development code: TDM-621) that gels when in contact with blood or other bodily fluids and stops bleeding upon contact with a wound site. We investigated its usefulness as a hemostatic material in animal and clinical studies. Methods: Before we began the clinical study, we demonstrated the hemostasis efficacy and safety of TDM-621 in animal experimental models. Twenty-five patients (22 men, 3 women) were enrolled in the clinical study, and the following procedures were performed: 1) coronary artery bypass graft (CABG) (n = 9), 2) abdominal aortic graft replacement (n = 4), and 3) peripheral artery bypass (n = 12). The TDM-621 material was applied to a total of 33 vascular anastomotic graft sites (some patients received material at more than one site). Both hemostatic efficacy and safety were examined. Results: A total of 33 anastomotic graft sites in 25 patients were evaluated, and the averaged primary and secondary efficacy rate was 94.5%. No postoperative bleeding or adverse events (including serious adverse events) with a causal relationship to treatment were observed. Conclusion: This study indicated that TDM-621 is a more effective and reliable hemostat than commonly-used general hemostatic agents and, therefore, will be very useful in several cardiovascular surgery applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Infectious Agent-Free Hemostatic Material (TDM-621) in Cardiovascular Surgery

Masuhara

Fujii

Watanabe

et al. 2012

Ann Thorac Cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…[1268][1269][1270][1271] Three RCTs comparing packing to no-packing reported no evidence of significant postoperative bleeding requiring intervention in their unpacked arms. [1268][1269][1270] This is further supported by a large retrospective series by Orlandi and Lanza 1271 of 165 patients undergoing ESS. This study observed that only 11.2% of patients required packing at the end of their sinus procedure, with no reports of significant postoperative bleeding in those left unpacked.…”

Section: Xd5 Surgical Principles/techniques: Use Of Packingmentioning

confidence: 99%

“…Sinus surgery itself is not characteristically associated with significant amounts of pain, although patients do frequently report discomfort from nasal packing and its removal. Level 1 evidence suggests that packing with absorbable dressings such as Nasopore R , 1285 HemoStase R , 1270 Sepragel R , 1291 and Floseal R 1274 are not associated with any increased pain, compared to unpacked cavities. In fact, in the studies that evaluated Sepragel R and Floseal R , patients reported less subjective discomfort on the treated side.…”

Section: Xd5 Surgical Principles/techniques: Use Of Packingmentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

Orlandi

Kingdom

Hwang

et al. 2016

Int Forum Allergy Rhinol

Self Cite

554

888

View full text Add to dashboard Cite

Background:The body of knowledge regarding rhinosinusitis (RS) continues to expand, with rapid growth in number of publications, yet substantial variability in the quality of those presentations. In an effort to both consolidate and critically appraise this information, rhinologic experts from around the world have produced the International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR:RS). Methods:Evidence-based reviews with recommendations (EBRRs) were developed for scores of topics, using previously reported methodology. Where existing evidence was insufficient for an EBRR, an evidence-based review (EBR) was produced. The sections were then synthesized and the entire manuscript was then reviewed by all authors for consensus. Results:The resulting ICAR:RS document addresses multiple topics in RS, including acute RS (ARS), chronic RS (CRS) with and without nasal polyps (CRSwNP and CRSsNP), recurrent acute RS (RARS), acute exacerbation of CRS (AE-CRS), and pediatric RS. Conclusion:As a critical review of the RS literature, ICAR:RS provides a thorough review of pathophysiology and evidence-based recommendations for medical and surgical treatment. It also demonstrates the significant gaps in our understanding of the pathophysiology and optimal management of RS. Too o en the foundation upon which these recommendations are based is comprised of lowerlevel evidence. It is our hope that this summary of the evidence in RS will point out where additional research efforts may be directed. C 2016 ARS-AAOA, LLC. Key Words:rhinosinusitis; chronic rhinosinusitis; acute rhinosinusitis; recurrent acute rhinosinusitis; evidence-based medicine; systematic review; endoscopic sinus surgery List of Abbreviations Used

show abstract

“…There was a significant statistical difference between APH and the other subgroups as to bleeding time (p<0.001). MPH technology provides fast and effective hemostasis in endoscopic nasal sinus surgeries, [9] dermatologic surgeries, [11] and laparoscopic surgeries [12] with no serious sideeffects or postoperative complications. With the increase of minimally-invasive surgical procedures with risks of bleeding, the importance of topical hemostats has also increased.…”

Section: Discussionmentioning

confidence: 99%

“…It is hydrolyzed by histamine and degraded to amylase and glucoamylase and then completely resorbed. Clinically, MPHs have produced very successful results in endoscopic nasal sinus surgery, [9] dermatologic surgery, [10,11] and laparoscopic surgery, causing no serious complications intra-and postoperatively. [12] Formerly, the hemostatic agent APH has not been used against bleeding of tissue defect in patients under anticoagulant therapy.…”

Section: Introductionmentioning

confidence: 99%

The efficacy of a hemostatic agent in anticoagulant drug-induced rat bleeding model

Sönmez¹,

Çavuş²,

Civelek³

et al. 2014

Ulus Travma Acil Cerrahi Derg

View full text Add to dashboard Cite

show abstract

Effect of Microporous Polysaccharide Hemospheres (MPH) on Bleeding after Endoscopic Sinus Surgery

Abstract: The use of MPH after ESS results in significantly less bleeding in the early postoperative period with no increase in pain, obstruction, or nasal discharge. Patients treated with MPH follow a normal postoperative recovery otherwise.

Cited by 68 publications

References 16 publications

Novel Infectious Agent-Free Hemostatic Material (TDM-621) in Cardiovascular Surgery

Novel Infectious Agent-Free Hemostatic Material (TDM-621) in Cardiovascular Surgery

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

The efficacy of a hemostatic agent in anticoagulant drug-induced rat bleeding model

Contact Info

Product

Resources

About